Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the
development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to …

Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …

Simple Summary The BRAFV600E mutation accounts for 8–10% of metastatic colorectal
cancer (mCRC) patients and it is an established prognostic factor. Median overall survival of …

Cancer therapies trigger diverse cellular responses, ranging from apoptotic death to
acquisition of persistent therapy-refractory states such as senescence. Tipping the balance …

Cancer cells often depend on multiple pathways for their growth and survival, resulting in
therapeutic resistance and the limited effectiveness of treatments. Combination therapy has …

Simple Summary Patient-derived xenografts (PDX) are valuable models in preclinical
oncology drug development. However, they are not well suited for testing immune-based …

Patient-derived cancer organoids hold great potential to accurately model and predict
therapeutic responses. Efficient organoid isolation methods that minimize post-collection …

The increasing incidence of skin cancer (SC) is a global health concern. The commonly
reported side effects and resistance mechanisms have imposed the pursuit for new …

Background While immune checkpoint blockade (ICB) is the current first-line treatment for
metastatic melanoma, it is effective for~ 52% of patients and has dangerous side effects. The …